<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02247362</url>
  </required_header>
  <id_info>
    <org_study_id>VAX2012Q-02</org_study_id>
    <nct_id>NCT02247362</nct_id>
  </id_info>
  <brief_title>Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years</brief_title>
  <official_title>Phase 1b/2 Double Blind, Randomized, Placebo Controlled Study of Safety and Immunogenicity of VAX2012Q: A Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VaxInnate Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VaxInnate Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One dose of escalating strengths of an investigational influenza vaccine, VAX2012Q&#xD;
      (Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine), will be evaluated for&#xD;
      safety and immunogenicity in healthy adults 65 to 75 years of age in this placebo-controlled&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate, in a stepwise fashion, dose levels for an&#xD;
      investigational quadrivalent influenza vaccine containing 2 influenza A strains and 2&#xD;
      influenza B strains. This is a multi-center, randomized, double-blind, placebo-controlled,&#xD;
      dose escalating study in which up to 200 healthy adults age 65-75 years will be administered&#xD;
      a single dose of either placebo or an investigational influenza vaccine (VAX2012Q,&#xD;
      Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine) at one of up to 3 dose&#xD;
      levels. Fifty or up to 75 subjects will be enrolled in each dose level. Data for safety and&#xD;
      immunogenicity will be collected for all dose levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Injection site and systemic symptoms will be collected for 21 days after vaccination. Other AEs assessed as related to vaccination will be collected at a 6 month and 1 year phone call.</measure>
    <time_frame>21 days post-immunization; follow up at 6 months and one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response to vaccine will be measured by serum HAI levels</measure>
    <time_frame>21 days post-immunization</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Vaccine Dose Group 12 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAX2012Q, 12 mcg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine Dose Group 20 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAX2012Q, 20 mcg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine Dose Group 16 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VAX2012Q; 16 mcg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine Diluent</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vaccine Diluent, F147, as placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VAX2012Q</intervention_name>
    <description>Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM</description>
    <arm_group_label>Vaccine Dose Group 12 mcg</arm_group_label>
    <arm_group_label>Vaccine Dose Group 16 mcg</arm_group_label>
    <arm_group_label>Vaccine Dose Group 20 mcg</arm_group_label>
    <other_name>Quadrivalent Recombinant Hemagglutinin Influenza Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vaccine Diluent</description>
    <arm_group_label>Vaccine Diluent</arm_group_label>
    <other_name>Vaccine Diluent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females aged 65-75 years of age at the time of vaccination in good health.&#xD;
             Individuals that are stably treated for hypertension may be eligible.&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Willing to receive the unlicensed vaccine&#xD;
&#xD;
          -  Willing to provide multiple blood specimens&#xD;
&#xD;
          -  Live in the community, independently or in an assisted living environment&#xD;
&#xD;
          -  Based on the results of the Short Portable Mental Status Questionnaire be rated as&#xD;
             normal or have no greater than mild severity dementia&#xD;
&#xD;
          -  As defined by the Canadian Study of Health and Aging Clinical Frailty Scale be a Class&#xD;
             1 to 5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preceding the administration of study vaccine, has received or will receive 1) any&#xD;
             licensed or investigational influenza vaccine product within 6 months, 2) any&#xD;
             investigational drug or any investigational vaccine product other than influenza&#xD;
             vaccine within the 30 days, 3) any licensed live vaccine other than influenza vaccine&#xD;
             within 4 weeks, 4) any licensed inactivated vaccine other than influenza vaccine&#xD;
             within 2 weeks&#xD;
&#xD;
          -  Planned receipt before the Day 21 blood draw of 1) any licensed or investigational&#xD;
             influenza vaccine product, 2) any investigational drug or any investigational vaccine&#xD;
             product other than influenza vaccine, 3) any licensed live vaccine other than&#xD;
             influenza vaccine, 4) any licensed inactivated vaccine other than influenza vaccine&#xD;
&#xD;
          -  History of excessive alcohol use, drug abuse or significant psychiatric illness&#xD;
&#xD;
          -  Has a chronic illness that is not medically stable, is receiving a concomitant therapy&#xD;
             in which the medication dose has not been stable for at least 3 weeks prior to&#xD;
             immunization or has any other condition that could interfere with the subject's&#xD;
             participation in the study or interpretation of the study results&#xD;
&#xD;
          -  Clinically significant abnormal liver function tests at screening&#xD;
&#xD;
          -  Subjects with Grade 2 or higher abnormalities in total bilirubin at screening&#xD;
&#xD;
          -  Subjects with any of the following laboratory abnormalities at screening: Creatinine&#xD;
             &gt;1.7mg/dL, Hemoglobin &lt; 11g/dL for females; &lt;12.5 g/dL for males, WBC &lt;2500cell/mm3 or&#xD;
             &gt; 15,000cell/mm3 and Platelet Count &lt;125,000cell/mm3&#xD;
&#xD;
          -  Positive serology of HBSAg, HCV or HIV antibodies&#xD;
&#xD;
          -  Having cancer or have received treatment for cancer within three years, excluding&#xD;
             minor skin cancers, which are allowed unless located at the vaccination site. Persons&#xD;
             with a history of cancer who are disease-free without treatment for three years or&#xD;
             more are eligible.&#xD;
&#xD;
          -  Persons with impaired immune responsiveness (of any cause), including Type 1 diabetes&#xD;
             mellitus and auto immune disorders or any known or suspected autoimmune disease&#xD;
&#xD;
          -  Persons with congenital immunodeficiency or history of acquired immunodeficiency, or&#xD;
             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within&#xD;
             the preceding six months.&#xD;
&#xD;
          -  Persons with a history of severe allergic reaction after previous vaccinations or&#xD;
             hypersensitivity to any seasonal influenza vaccine component&#xD;
&#xD;
          -  Persons with a history of Guillain-Barré Syndrome&#xD;
&#xD;
          -  Receipt or donation of blood or blood products 8 weeks prior to vaccination or during&#xD;
             the three week study period following vaccination&#xD;
&#xD;
          -  Acute disease within 72 hours prior to vaccination.&#xD;
&#xD;
          -  An oral temperature &gt;100.4°F (38°C)&#xD;
&#xD;
          -  Systolic blood pressure &lt; 85 mm Hg and subjects whose hypertension is untreated or&#xD;
             unstable with antihypertensive therapy or that have systolic BP ≥ 160 mm Hg or&#xD;
             diastolic BP ≥ 100 mm Hg requiring medical intervention with more than one drug or&#xD;
             more intensive therapy than previously used or indicated.&#xD;
&#xD;
          -  Body Mass Index &gt;40&#xD;
&#xD;
          -  Disorders of coagulation&#xD;
&#xD;
          -  Women less than 1 year post menopausal&#xD;
&#xD;
          -  A clinical diagnosis of influenza within the previous 6 months&#xD;
&#xD;
          -  Any other condition or circumstance which, in the opinion of the Principal&#xD;
             Investigator, poses an unacceptable risk for participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynda Tussey, PHD</last_name>
    <role>Study Director</role>
    <affiliation>VaxInnate Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Q-Pharm Pty Limited</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMAX, a division of IDT Australia Limited</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Limited</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>September 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Hemagglutinins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

